Continued Strong Growth and Acquisition in the U.S. STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: NINE-MONTH PERIOD (JAN-SEPT 2012) Revenue MSEK 82.3 (35.4) Research and development expenses MSEK 23.4 (19.5) Operating profit MSEK 13.3 (-11.4) Net profit after tax MSEK 42.1 (-10.8) Earnings per share SEK 4.40 (-1.47) Operating cash flow per share SEK 1.27 (-2.84) THIRD QUARTER (JUL-SEPT 2012) Revenue MSEK 26.7 (21.9) Research and development expenses MSEK 7.6 (5.8) Operating profit MSEK 4.0 (4.9) Net profit after tax MSEK 2.8 (5.4) Earnings per share SEK 0.29 (0.59) Operating cash flow per share SEK 0.66 (-1.63) SIGNIFICANT EVENTS DURING THE THIRD QUARTER...
0 Responses to Moberg Derma Interim Report January - September 2012